DDInter915 DDInter1588
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. Indacaterol is provided as its maleate salt form. Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed.
Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. Ribociclib was approved by the U.S. FDA in March, 2017 as Kisqali.
Indacaterol {u} (Compound) treats {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Hydrocortisone
Hydrocortisone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ribociclib
Indacaterol {u} (Compound) binds {v} (Gene) ADRB1
ADRB1 {u} (Gene) is bound by {v} (Compound) Formoterol
Formoterol {u} may lead to a major life threatening interaction when taken with {v} Ribociclib
Indacaterol {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Betamethasone
Betamethasone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ribociclib
Indacaterol {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Mirabegron
Mirabegron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ribociclib
Indacaterol {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic beta2-Agonists
Adrenergic beta2-Agonists {u} (Pharmacologic Class) includes {v} (Compound) Salbutamol
Salbutamol {u} may lead to a major life threatening interaction when taken with {v} Ribociclib
Indacaterol {u} (Compound) binds {v} (Gene) ADRB2
ADRB2 {u} (Gene) is upregulated by {v} (Compound) Irinotecan
Irinotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ribociclib
Indacaterol {u} (Compound) causes {v} (Side Effect) Cardiac disorder
Cardiac disorder {u} (Side Effect) is caused by {v} (Compound) Cladribine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Ribociclib
Indacaterol {u} (Compound) causes {v} (Side Effect) Cardiac disorder
Cardiac disorder {u} (Side Effect) is caused by {v} (Compound) Mirabegron
Mirabegron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ribociclib
Indacaterol {u} (Compound) causes {v} (Side Effect) Dry mouth
Dry mouth {u} (Side Effect) is caused by {v} (Compound) Tolterodine
Tolterodine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ribociclib
Indacaterol {u} (Compound) binds {v} (Gene) ADRB2
ADRB2 {u} (Gene) is upregulated by {v} (Compound) Thioridazine
Thioridazine {u} may lead to a major life threatening interaction when taken with {v} Ribociclib
Indacaterol (Compound) treats asthma (Disease) and asthma (Disease) is treated by Hydrocortisone (Compound) and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Indacaterol (Compound) binds ADRB1 (Gene) and ADRB1 (Gene) is bound by Formoterol (Compound) and Formoterol may lead to a major life threatening interaction when taken with Ribociclib
Indacaterol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Betamethasone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Indacaterol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Mirabegron (Compound) and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Indacaterol (Compound) is included by Adrenergic beta2-Agonists (Pharmacologic Class) and Adrenergic beta2-Agonists (Pharmacologic Class) includes Salbutamol (Compound) and Salbutamol may lead to a major life threatening interaction when taken with Ribociclib
Indacaterol (Compound) binds ADRB2 (Gene) and ADRB2 (Gene) is upregulated by Irinotecan (Compound) and Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Indacaterol (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Cladribine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Ribociclib
Indacaterol (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Mirabegron (Compound) and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Indacaterol (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Tolterodine (Compound) and Tolterodine may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Indacaterol (Compound) binds ADRB2 (Gene) and ADRB2 (Gene) is upregulated by Thioridazine (Compound) and Thioridazine may lead to a major life threatening interaction when taken with Ribociclib